|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.82 USD | +0.19% |
|
-3.82% | -15.88% |
| 02:45pm | BMO Capital Adjusts Price Target on Incyte to $56 From $64 | MT |
| Apr. 01 | Incyte, China Medical System Sign Collaboration, License Agreement | MT |
Sept 21 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Incyte Corp's cream for treating inflammatory skin condition atopic dermatitis, commonly called eczema, in adolescents and adults. (Reporting by Bhanvi Satija and Manojna Maddipatla; Editing by Vinay Dwivedi)
| 1st Jan change | Capi. | |
|---|---|---|
| -15.88% | 11.86B | |
| -5.99% | 84.46B | |
| +3.95% | 40.85B | |
| -26.37% | 27.69B | |
| +52.72% | 24.28B | |
| -6.59% | 17.09B | |
| -32.37% | 13.67B | |
| -10.45% | 11.79B | |
| -2.62% | 8.07B | |
| +0.53% | 7.51B |
INCYTE CORPORATION 
